China-based Leads Biolabs has entered an exclusive global partnership with Dianthus Therapeutics for its preclinical bispecific fusion protein LBL-047 – targeting BDCA2 and TACI pathways in autoimmune diseases – through a potential USD-1-billion agreement including USD 38 million upfront and near-term milestone payments. The first-in-class candidate selectively depletes plasmacytoid dendritic cells to reduce type one interferon (IFN-I) production while inhibiting BlyS and APRIL signalling for broad autoimmune applications. Leads retains Greater China rights and receives tiered royalties on ex-China net sales ranging from mid-single to low-double digits.

LBL-047's dual mechanism addresses key drivers in autoimmune pathogenesis, including aberrant interferon activation and B-cell dysregulation present in systemic lupus erythematosus (SLE), Sjogren's syndrome and other rheumatic conditions. The long-acting fusion protein design enables sustained pathway inhibition with reduced dosing frequency compared to conventional monoclonal antibodies (mAbs). Dianthus Therapeutics gains a novel asset complementing its complement pathway portfolio while Leads advances its globalisation strategy following previous out-licensing deals for immuno-oncology candidates.

According to PharmCube's NextBiopharm® database, this is Leads Biolabs' largest licensing deal. Click here to request a free trial for NextBiopharm®.